Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
Perales, Miguel‐Angel , Awan, Farrukh T. , Patel, Jinalben , Castagna, Luca , Angelucci, Emanuele , Finel, Hervé , Kulagin, Alexander , Glass, Bertram , Herrera, Alex F. , Blaise, Didier , Kharfan‐Dabaja, Mohamed A. , Halahleh, Khalid , Jones, Richard J., Lynch, Ryan C. , Sauter, Craig S. , Ahn, Kwang Woo , Sureda, Anna , Boumendil, Ariane , Patel, Jinalben , Castagna, Luca , Angelucci, Emanuele , Finel, Herve , Corradini, Paolo , Herrera, Alex F , Blaise, Didier , Kharfan-Dabaja, Mohamed A , Halahleh, Khalid , Ahmed, Sairah , Martínez, Carmen , Giebel, Sebastian , Montoto, Silvia , Ahmed, Nausheen , de Lima, Marcos , Shadman, Mazyar , Ahn, Kwang W , Hamadani, Mehdi , Sureda, Anna , Perales, Miguel-Angel , Awan, Farrukh T , Boumendil, Ariane , Ahmed, Sairah , Montoto, Silvia , Ahmed, Nausheen , Lima, Marcos de , Shadman, Mazyar , Hamadani, Mehdi , Bazarbachi, Ali

Blood | July 7, 2025 | Volume: 146 | Issue: 8 | Pages: 1011-1029

10.1182/blood.2024027197 | PMID 40623049 Get It

Abstract Checkpoint inhibitors (CPIs) have shown remarkable efficacy in Hodgkin lymphoma (HL), and are now used routinely. While allogeneic hematopoietic cell transplantation (allo-HCT) remains a curative option for HL, there are concerns prior CPIs may exacerbate post–allo-HCT complications, particularly graft-versus-host disease (GVHD), and lead to worse outcomes. Given the relative paucity of data, we performed a Center for International Blood and Marrow Transplant Research/European Society for Blood and Marrow Transplantation study to examine the impact of prior CPIs in allo-HCT. We included 2186 adult patients aged >18 years who received a first allo-HCT using a matched related, unrelated, or haploidentical donor from 2008 to 2023. Twenty-seven percent of patients received prior CPIs. GVHD prophylaxis was posttransplant cyclophosphamide (PTCy) in 55.8% of patients in the CPI cohort, and 35% in the non-CPI cohort. Median follow-up among survivors was longer for the non-CPI (39 months) than CPI cohort (16.5 months). In multivariate analysis, prior CPI exposure did not affect overall survival (OS) or nonrelapse mortality, but resulted in improved progression-free survival (non-CPI vs CPI hazard ratio [HR], 0.81; 0.67-0.98; P = .03) and lower relapse incidence (HR, 0.58; 0.45-0.76; P < 001). While grade 2 to 4 (HR, 1.26; 1.04-1.53; P = .02) and 3 to 4 (HR, 1.41; 1.04-1.92; P = .03) acute GVHD (aGVHD) were increased, differences in chronic GVHD (cGVHD) were not significant. PTCy–based GVHD prophylaxis resulted in improved OS, lower grade 2 to 4 aGVHD, and cGVHD in patients with prior CPI exposure. In summary, allo-HCT should still be considered a curative option for patients with HL in the era of CPIs.
Recombinant herpes zoster vaccine lowers shingles complication risk in patients with inflammatory bowel disease
Wang, Yichen , Huang, Yuting , Hashash, Jana, Odah, Tarek , Caldera, Freddy, Caldera, Freddy , Caldera, Freddy , Huang, Yuting , Wang, Yichen , Hayney, Mary S. , Farraye, Francis A.

Journal of Crohn’s and Colitis | July 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf116 | PMID 40623013 Get It

Abstract Background Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ) infection due to innate immune abnormalities and use of immunosuppressive therapy. The recombinant zoster vaccine (RZV) is recommended, but its efficacy in preventing recurrent HZ among patients with IBD is not well established. Methods Using data from the TriNetX Linked Network, we conducted a retrospective cohort study of adults (≥18 years) with IBD and a prior uncomplicated HZ episode. Patients with IBD who received RZV were propensity score-matched 1:1 with those who did not. The primary outcome was subsequent HZ complications. Secondary outcomes included subtypes of HZ complications and recurrent uncomplicated HZ. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated via Cox proportional hazards models. Results After matching, 1260 vaccinated and 1260 unvaccinated patients with IBD were included. Compared to the unvaccinated cohort, patients receiving RZV had a significantly reduced incidence of HZ complications (7.4% vs. 14.5%; HR, 0.75; 95% CI, 0.58–0.97; P = .028). Postherpetic neuralgia was notably decreased (5.8% vs. 12.5%; HR, 0.66; P = .010), and no central nervous system involvement occurred among vaccinated patients. Protective effects were more pronounced in patients with ulcerative colitis, females, and those not receiving immunosuppressive therapy. Conclusions RZV substantially lowers the risk of HZ complications in patients with IBD, offering significant clinical benefits to those at high risk due to immunosuppression. These findings underscore the importance of RZV as part of preventive care strategies in patients with IBD.
Reinforcing the role of magnesium in preventing cisplatin-induced nephrotoxicity: real-world evidence and clinical implications
Nardelli, Luca , Mohan, Arjunmohan , Herrmann, Sandra M. , Herrmann, Sandra M

Clinical Kidney Journal | July 7, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1093/ckj/sfaf212 | PMID 40755966 Get It

Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma
Dong, Yawen , Li, Zhihao , Podrascanin, V. , Eaton, John E. , Ilyas, Sumera I. , Gores, Gregory J. , Warner, Susanne G. , Diwan, Tayyab S. , Nagorney, David M. , Heimbach, Julie K. , Smoot, Rory L. , Taner, Timuçin , Gores, Gregory J. , Starlinger, Patrick , Smoot, Rory L , Ilyas, Sumera Irie , Warner, Susanne G , Li, Zhihao , Heimbach, Julie K , Dong, Yawen , Starlinger, Patrick

Hepatology | July 7, 2025 | Volume: 83 | Issue: 5 | Pages: 1128-1142

10.1097/hep.0000000000001449 | PMID 40622853 Get It

Background and Aims: The optimal treatment strategy for de novo perihilar cholangiocarcinoma (pCCA) remains debated. This study compares outcomes between liver transplantation following neoadjuvant chemoradiation (RT+LT) and liver resection (LR), with (LR+VR) and without vascular resection (LR w/o VR). Approach and Results: This single-center, retrospective study included patients with de novo perihilar cholangiocarcinoma treated at the Mayo Clinic Rochester (1993–2023) with curative-intent surgery. Patients underwent either (1) LR, classified as LR+VR or LR w/o VR, or (2) RT+LT following the transplant protocol. Overall survival (OS) and recurrence-free survival were analyzed using as-treated and intention-to-treat approaches, incorporating competing risk analysis and direct matching. In the as-treated analysis, RT+LT showed superior median OS compared with LR w/o VR (78.0 vs. 58.2 mo, p =0.03) and LR+VR (25.8 mo, p <0.001). Considering dropout rates (RT+LT: 41%, LR: 28%), intention-to-treat analysis showed no significant OS difference between LR and RT + LT (31.7 vs. 38.5 mo, p =0.19). In matched as-treated analysis, RT + LT had no significant survival benefit over LR w/o VR (50.6 vs. 140.6 mo, p =0.08) or LR+VR (25.8 mo, p =0.11). Perioperative mortality was 4% (RT+LT), 7% (LR w/o VR), and 8% (LR + VR). Conclusions: Both LR and RT+LT achieve excellent oncological outcomes in selected patients with de novo perihilar cholangiocarcinoma. Key challenges remain dropouts during neoadjuvant therapy in patients planned for LT and high perioperative mortality for patients undergoing LR. OS doubles in patients undergoing LR+VR compared with dropouts, supporting LR+VR as a viable option for patients who are ineligible for LT. Appropriate patient selection is crucial, as those not undergoing surgery suffer from a dismal prognosis.
Multicenter Insights into Peritoneal Dialysis for Autosomal Dominant Polycystic Kidney Disease
Debeh, Fadi George Munairdjy , Ghanem, Ahmad , Rangarajan, Vineetha, Borghol, Abdul Hamid , Paul, Stefan , Alkhatib, Bassel , Nader, Nay , Antoun, Mikhail D., Hanna, Dana, Souvalian, Levon , Li, Zhuo, Gregory, Adriana , Kline, Timothy L. , Manohar, Sandhya , Porter, Ivan E. , Dillon, John , Kattah, Andrea G. , Khalillullah, Sayeed , Baker, Lyle W. , Trautman, Christopher L. , Aslam, Nabeel , Li, Zhuo , Munairdjy Debeh, Fadi George , Bou Antoun, Marie Therese , Kline, Timothy L , Mao, Michael A , Manohar, Sandhya , Porter, Ivan , Dillon, John J , Kattah, Andrea G , Khalillullah, Sayeed , Baker, Lyle Wesley , Trautman, Christopher L , Chebib, Fouad T , Aslam, Nabeel , Rangarajan, Vineetha, Nader, Nay , Hanna, Dana, Mao, Michael A. , Hickson, LaTonya J. , Chebib, Fouad T.

Kidney360 | July 7, 2025 | Volume: 6 | Issue: 11 | Pages: 1918-1927

10.34067/kid.0000000888 | PMID 40622773 Get It

Key Points This study demonstrates that peritoneal dialysis is a safe and feasible option for patients with autosomal dominant polycystic kidney disease, even with high cystic organ volumes. Larger organ volumes, including height-adjusted cumulative kidney and liver volume, were not associated with increased peritoneal dialysis–related complications. Background Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent genetic kidney disorder and the fourth leading cause of kidney failure. Peritoneal dialysis (PD), preferred for its home-based convenience and cost-effectiveness, is often underutilized in ADPKD because of concerns over enlarged kidneys and heightened risk of complications. Methods This retrospective cohort study used data from the Mayo Clinic Polycystic Kidney Disease Database to evaluate individuals with ADPKD undergoing PD. We analyzed demographics, clinical parameters, and PD-related parameters. Complications were correlated with kidney and liver volumes derived from pre-kidney failure imaging. Results A total of 155 individuals with ADPKD on PD were included, of whom 45.1% were male. The mean age at PD initiation was 54.3±12.8 years, and the mean body mass index was 28.0±7.0 kg/m 2 . The median duration of PD was 24.3 months (interquartile range [IQR], 10.7–43.1), with 21.9% transitioning to hemodialysis. The most common complications were abdominal hernias (30.3%) and peritonitis (23.9%), with a peritonitis rate of 0.11 episodes per patient-year. Imaging analyses performed on a subset of 50 patients showed a median height-adjusted total kidney liver volume of 2731.9 ml/m (IQR, 2102.5–3131.1) and a median height-adjusted total kidney volume of 1303.5 ml/m (IQR, 733.1–1829.4). Kaplan–Meier analysis demonstrated no differences in complications rates on the basis of height-adjusted total kidney liver volume or height-adjusted total kidney volume (above versus below median values) or body mass index categories. Multivariate Cox regression analysis revealed that higher height-adjusted cumulative organ volume was associated with a lower risk of PD-related complications (hazard ratio=0.56, P = 0.026). Conclusions PD is a safe and feasible treatment option for patients with ADPKD, with no increased risk of PD-related complications associated with larger height-adjusted cumulative organ volumes. Infectious complication rates in this cohort were within International Society of Peritoneal Dialysis guideline thresholds, further supporting the safety of PD in this population.
Pain Management in Autosomal Dominant Polycystic Kidney Disease
Borghol, Abdul Hamid , Debeh, Fadi George Munairdjy , Ghanem, Ahmad , Antoun, Mikhail D., Rangarajan, Vineetha, Mina, Jonathan , Hassanein, Mohamed , Baker, Lyle W. , Gupta, Sahil , Mao, Shennen A. , Munairdjy Debeh, Fadi George , Bou Antoun, Marie Therese , Hunt, Christine , Hogan, Marie C , Mao, Michael A , Chebib, Fouad T , Baker, Lyle Wesley , Mao, Shennen A , Rangarajan, Vineetha, Hogan, Marie C. , Mao, Michael A. , Chebib, Fouad T.

Kidney360 | July 7, 2025 | Volume: 6 | Issue: 9 | Pages: 1618-1631

10.34067/kid.0000000907 | PMID 40622770 Get It

Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disorder. It is primarily caused by pathogenic variants in the PKD1 or PKD2 genes. This leads to the development of numerous kidney cysts, which can result in kidney enlargement and progression to kidney failure. Pain is a common symptom in ADPKD and can negatively affect quality of life (QOL). This pain is often due to the continuous growth of kidney and liver cysts or associated cystic complications. We present a case of a 29-year-old woman with ADPKD who experienced chronic, refractory right-sided flank pain that significantly affected her QOL. Her pain persisted despite taking daily multimodal analgesics and undergoing multiple invasive interventions. She had an unusual asymmetric disease with the right kidney accounting for only 24% of her kidney function. After exhausting all other pain control strategies, she underwent right nephrectomy and partial hepatectomy, which led to substantial improvement in pain and QOL. This review describes the causes, manifestations, and management strategies for abdominal and/or flank pain in ADPKD, including a practical stepwise algorithm to guide clinicians in managing pain and improve QOL of patients with ADPKD. Pain in ADPKD can either be acute or chronic and can lead to significant physical and psychologic distress. Effective pain management in ADPKD requires a multidisciplinary approach, incorporating both nonpharmacologic and pharmacologic interventions such as gabapentin or tolvaptan in select cases. Interventions considered in ADPKD pain control include cyst aspiration with sclerotherapy, celiac plexus blockade, spinal cord stimulation, renal denervation, or nephrectomy.
Oral Indomethacin for Chronic Pancreatitis: Results From the PAIR Randomized Placebo-Controlled Trial
Vege, Santhi Swaroop , Hart, Phil A. , Saloman, Jami L. , Xu, Jun , Li, Liang , Cruz‐Monserrate, Zobeida , Palermo, Tonya M. , Yadav, Dhiraj , Topazian, Mark , Conwell, Darwin L. , Saloman, Jami L , Han, Samuel , Xu, Jun , Hill, Rachel, Hao, Wenrui

Clinical and Translational Gastroenterology | July 7, 2025 | Volume: 16 | Issue: 9 | Pages: e00888

10.14309/ctg.0000000000000888 | PMID 40622408 Get It

INTRODUCTION: Chronic pancreatitis (CP) remains difficult to manage with few treatment options. Prior studies have implicated prostaglandin E 2 (PGE 2 ) in mediating chronic inflammation in the pancreas. Therefore, we aimed to evaluate whether indomethacin, a cyclooxygenase-2 enzyme inhibitor, would reduce PGE 2 levels in CP. METHODS: In this pilot multicenter randomized controlled trial, participants with CP received oral indomethacin (50 mg) or placebo twice daily for 28 days. Measurement of PGE 2 levels in pancreatic fluid collected endoscopically after secretin administration at baseline and posttreatment (day 28) was performed. Quality of life and pain were also assessed at baseline and posttreatment. RESULTS: A total of 27 participants were randomized (indomethacin = 13, placebo = 14). Although PGE 2 levels decreased after treatment in pancreas fluid, plasma, and saliva in the indomethacin group, there was no significant difference in mean change in pancreas fluid PGE 2 levels between the indomethacin and placebo groups (−457.7 pg/mL vs −840.4 pg/mL, P = 0.25). There was also no significant change in pain severity composite score (−1.3 indomethacin vs −0.5 placebo, P = 0.33), but the improvement in pain interference score (−2.9 indomethacin vs −0.4, P = 0.058) trended toward significance. There was no difference in adverse events between the 2 groups. DISCUSSION: In this phase 1/2 study, oral indomethacin was safe and well tolerated by patients with CP. Although there was no significant difference in change in PGE 2 levels, further studies are needed to determine the effect of indomethacin on the inflammatory pathway of CP and patient-centered outcomes.
Invasive and Non-Invasive Neuromodulation for the Treatment of Substance Use Disorders: A Review of Reviews
Oesterle, Tyler , Bormann, Nicholas L. , Al‐Soleiti, Majd , Kung, Simon , Singh, Balwinder , McGinnis, Michele , Costa, Sabrina Corrêa da , Rummans, Teresa A. , Chauhan, Mohit , Cabrera, Juan M. Rojas , Vettleson-Trutza, Sara A. , Scheitler, Kristen M. , Shin, Hojin , Lee, Kendall H. , Gold, Mark S. , Oesterle, Tyler S , McGinnis, Michele T , Correa da Costa, Sabrina, Rummans, Teresa , Rojas Cabrera, Juan M , Singh, Balwinder , Vettleson-Trutza, Sara , Bormann, Nicholas L , Chauhan, Mohit

Brain Sciences | July 7, 2025 | Volume: 15 | Issue: 7 | Pages: 723

10.3390/brainsci15070723 | PMID 40722314 Get It

Background: Invasive and non-invasive neuromodulation in psychiatry represents a burgeoning field that leverages advanced neuromodulation techniques to address substance use disorders (SUDs). Aims: This narrative review synthesizes findings from multiple reviews to evaluate the efficacy of neuromodulation in treating SUDs. Methods: A comprehensive literature search was conducted between December 2024 and April 2025, focusing on systematic reviews and meta-analyses that examined various neuromodulation modalities, including repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS). The selected reviews were analyzed to identify common themes, outcomes, and gaps in the current understanding of these treatments for SUDs. Results: 11 reviews met the final inclusion criteria; 5 focused on non-invasive neuromodulation (rTMS, tDCS) and 6 on invasive neuromodulation (DBS). Non-invasive neurostimulation was associated with modest improvements in craving and cognitive dysfunction in individuals with SUDs. Similarly, invasive neuromodulation (DBS), through high-frequency stimulation of the bilateral nucleus accumbens, appeared to reduce cravings and improve comorbid psychiatric symptoms in both preclinical and human studies. Importantly, small sample sizes, heterogeneity in targets and stimulation protocols, and short follow-up periods significantly limit the generalizability of current findings from both non-invasive and invasive neuromodulation studies. Conclusions: As novel and more effective therapies for the treatment of SUD are desperately needed, procedural interventional psychiatry holds promise. However, despite encouraging results, existing evidence is still preliminary, and larger, rigorously designed studies are warranted to further establish the safety and efficacy of neuromodulatory interventions for SUD treatment.
The evolving therapeutic landscape of Graves’ disease in adults: present and future
Dosiou, Chrysoula , Stan, Marius N , Dosiou, Chrysoula , Stan, Marius N.

European Thyroid Journal | July 7, 2025 | Volume: 14 | Issue: 4 | Pages: No page available

10.1530/etj-25-0078 | PMID 40622195 Get It

Abstract The therapeutic landscape of Graves’ hyperthyroidism has been rapidly evolving in the past few years. There has been a shift worldwide toward antithyroid drugs as the preferred first-line therapy with significant interest in thyroid function preservation, even if it requires more than 2 years of antithyroid drug treatment. This approach, long term antithyroid drug therapy, has gained traction as a therapeutic option after it has been shown to be safe and associated with significantly higher rates of remission than the traditional 18-month course of medical treatment. In parallel, we see, after 80 years of antithyroid drugs as the only medical therapy available for Graves’ disease, a strong interest in new drug development that follows more closely the pathophysiology of the disease. These approaches span the spectrum of targeting antigen presentation, B cell activation, TSHR antibody cycle and TSHR signaling. Separately, advances in wearable devices and artificial intelligence models present new opportunities for more timely diagnosis, monitoring, and treatment of patients with Graves’ disease. Finally, new therapies will pose novel challenges in the management of patients that will necessitate adjustments to our clinical practices and development of guidelines suited for these new therapeutic options.
Reattempting the Whipple: Surgical and Oncologic Outcomes After Failed Initial Resection
Verastegui, Alfredo , Zamorano, Alicia Amairan G. , Mount, Jared , Chan, Carlos , Verastegui, Alfredo , Stauffer, John

The American Surgeon™ | July 7, 2025 | Volume: 92 | Issue: 1 | Pages: 193-200

10.1177/00031348251358447 | PMID 40622198 Get It

Background Pancreatoduodenectomy (PD) is the only curative treatment for pancreatic cancer. Neoadjuvant therapy (NAT) has enhanced survival, especially for downstaging advanced tumors, while also introducing complexities and new complications. Despite surgical advances, some PD attempts remain unsuccessful. The management of these cases is not well defined. This study analyzes outcomes of repeat PD performed by two high-volume surgeons following previously unsuccessful attempts. Methods We retrospectively analyzed patients with pancreatic neoplasm undergoing successful pancreaticoduodenectomy (2013-2024) at two high-volume centers under two experienced surgeons. Only cases with prior aborted PD attempts for non-metastatic disease were included. Data from institutional records provided outcomes on failure reasons, procedure timing, surgical details, and 90-day complications. Results Of the 858 PD cases, 18 patients (2.1%; 12 males, 6 females; median age 69 years) had prior unsuccessful PD attempts at other institutions. Initial tumors were borderline resectable (33.3%), resectable (22.2%), or locally advanced (22.2%). Main causes for initial failure were vascular involvement (41.2%) and tumor infiltration (17.6%). Median time between attempts was 246 days, with 77.8% receiving chemotherapy before the second attempt. The second procedure achieved R0 resection in 94.4% of cases. Major 90-day complications occurred in 23.5% of patients, with no perioperative mortality. Disease recurrence occurred in 38.9% within the first year. Conclusion Repeat PD after an aborted attempt is feasible in select patients at specialized centers. However, complication and recurrence rates emphasize the need for careful patient selection. Further research is needed to optimize management strategies.